Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc H Scheetz

Showing results (71-80 of 221) with videos related to

Pageof 23
Sort By:
Pharmacotherapy|July 31, 2013
Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitalsSusan L Davis, Marc H Scheetz, John A Bosso, et al.
The Journal of Antimicrobial Chemotherapy|May 31, 2022
Does calculation method matter for targeting vancomycin area under the curve?Jack Chang, Dhara Patel, Ana Vega, et al.
Pharmacotherapy|September 20, 2011
Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic modelMarc H Scheetz, Maureen K Bolon, John S Esterly, et al.
Expert Review of Anti-Infective Therapy|February 27, 2016
Carbapenem susceptibility breakpoints, clinical implications with the moving targetJ Nicholas O'Donnell, Cristina M Miglis, Jane Y Lee, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2012
Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratificationJohn S Esterly, Jamie Wagner, Milena M McLaughlin, et al.
International Journal of Antimicrobial Agents|April 13, 2010
Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patientsE Paul O'Donnell, Kimberly K Scarsi, Marc H Scheetz, et al.
ACR Open Rheumatology|July 30, 2020
A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 PandemicMarc H Scheetz, Maximilian F Konig, Philip C Robinson, et al.
Antimicrobial Agents and Chemotherapy|April 10, 2024
Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infectionsAndrew S Haynes, Zixuan Wei, Peter Anderson, et al.
Clinical Pharmacokinetics|May 30, 2020
Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational StudyAhmed A Mahmoud, Sean N Avedissian, Abbas Al-Qamari, et al.
Antimicrobial Agents and Chemotherapy|September 11, 2013
Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysisAngela S Loo, Michael Neely, Evan J Anderson, et al.
Pageof 23

Showing results (71-80 of 221) with videos related to

Sort By:
Pageof 23
Pharmacotherapy|July 31, 2013
Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitalsSusan L Davis, Marc H Scheetz, John A Bosso, et al.
The Journal of Antimicrobial Chemotherapy|May 31, 2022
Does calculation method matter for targeting vancomycin area under the curve?Jack Chang, Dhara Patel, Ana Vega, et al.
Pharmacotherapy|September 20, 2011
Life-years gained with meropenem over ciprofloxacin in penicillin-allergic patients with gram-negative bacilli sepsis: results of a probabilistic modelMarc H Scheetz, Maureen K Bolon, John S Esterly, et al.
Expert Review of Anti-Infective Therapy|February 27, 2016
Carbapenem susceptibility breakpoints, clinical implications with the moving targetJ Nicholas O'Donnell, Cristina M Miglis, Jane Y Lee, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2012
Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratificationJohn S Esterly, Jamie Wagner, Milena M McLaughlin, et al.
International Journal of Antimicrobial Agents|April 13, 2010
Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patientsE Paul O'Donnell, Kimberly K Scarsi, Marc H Scheetz, et al.
ACR Open Rheumatology|July 30, 2020
A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 PandemicMarc H Scheetz, Maximilian F Konig, Philip C Robinson, et al.
Antimicrobial Agents and Chemotherapy|April 10, 2024
Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infectionsAndrew S Haynes, Zixuan Wei, Peter Anderson, et al.
Clinical Pharmacokinetics|May 30, 2020
Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational StudyAhmed A Mahmoud, Sean N Avedissian, Abbas Al-Qamari, et al.
Antimicrobial Agents and Chemotherapy|September 11, 2013
Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysisAngela S Loo, Michael Neely, Evan J Anderson, et al.
Pageof 23